ACOG

8-K - Alpha Cognition Inc. (0001655923) (Filer)

Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms. Sensenig brings decades of leadership experience across the pharmaceutical and biotechnology industries, with deep expertise in finance, corporate strategy, and operations. "On behalf of the entire Board of Directors, it is a pleasure to welcome Bethany Sensenig, a highly accomplished industry leader," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc. "Her broad experience acro

4 - Alpha Cognition Inc. (0001655923) (Issuer)

3 - Alpha Cognition Inc. (0001655923) (Issuer)

Craig Hallum initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $14.00

Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on April 14, 2026, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 20,000 shares of common stock to a new non-executive employee under the Company's 2026 Inducement Grant Plan. The 2026 Inducement Grant Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of the Company. The Compensation Committee approved the st

8-K - Alpha Cognition Inc. (0001655923) (Filer)

Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,589,099 on March 31, 2026. The patent, titled "ALPHA-1062 for treating Traumatic Brain Injury," includes claims covering methods of treating both confirmed and suspected traumatic brain injury (TBI) using ALPHA-1062. This newly issued patent strengthens Alpha Cognition's intellectual property portfolio and complements existing patents supporting both ALPHA-1062 and ZUNVEYL®. The patent provides protect

10-K - Alpha Cognition Inc. (0001655923) (Filer)

4 - Alpha Cognition Inc. (0001655923) (Issuer)

8-K - Alpha Cognition Inc. (0001655923) (Filer)

4 - Alpha Cognition Inc. (0001655923) (Issuer)

8-K - Alpha Cognition Inc. (0001655923) (Filer)

Alpha Cognition generated fourth quarter 2025 ZUNVEYL net product revenue of $2.5 million, contributing to full year 2025 total revenue of $10.2 million Fourth quarter bottles dispensed increased 62% quarter-over-quarter to 4,941, with December representing the strongest month since launch Executed second national PBM contract and initiating three studies to further support ZUNVEYL's positioning in long-term care Alzheimer's patients Cash and cash equivalents totaled $66 million at year-end 2025, supporting the company's continued target of operating profitability in 2027 Company to host conference call and webcast today, March 26, at 4:30 p.m. ET Alpha Cognition Inc. (ACOG: NASDA

4 - Alpha Cognition Inc. (0001655923) (Issuer)

4 - Alpha Cognition Inc. (0001655923) (Issuer)

4 - Alpha Cognition Inc. (0001655923) (Issuer)

Management to host conference call on Thursday, March 26, 2026 at 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, March 26, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its fourth quarter and full year financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website at www.alphacognition.com/investors/news/.

4 - Alpha Cognition Inc. (0001655923) (Issuer)

Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company"), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical data on ZUNVEYL at the American Association of Geriatric Psychiatrists (AAGP), taking place April 16-20, 2026 and the Neuroscience Education Institute (NEI) Spring Congress, taking place May 1-3, 2026. The Company will share the following poster presentations: Beyond Cholinesterase Inhibition: The Clinical Benefits of Galantamine- and Benzgalantamine-Mediated Nicotinic Receptor Modulation in Alzheimer's Disease Presenter: Kurt Grady, PharmD (Poster S49) Presentati

4 - Alpha Cognition Inc. (0001655923) (Issuer)

4 - Alpha Cognition Inc. (0001655923) (Issuer)

SCHEDULE 13G/A - Alpha Cognition Inc. (0001655923) (Subject)

4 - Alpha Cognition Inc. (0001655923) (Issuer)

Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition," "ACI," or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the first patient in BEACON, a Phase 4 real world effectiveness study, to assess the impact of ZUNVEYL® in the Long-Term Care (LTC) setting. The BEACON study is designed to assess the real-world impact of ZUNVEYL on cognition, neuropsychiatric symptoms, safety, and tolerability in patients with Alzheimer's disease residing in nursing homes. By generating data in routine clinical practice, the study aims to complement findings from earlier clinical trials and